The presence of mutations that interest the spliceosome genes (e.g., SF3B1, SRSF2, U2AF1 genes) suggests AML progression from MDS, even in patients with a negative history of MDS diagnosis [4]. Here, SF3B1 is linked to myelodysplastic syndrome.